Results are sent directly to patients and are tailored specifically to reduce anxiety and support informed action. This approach leads to faster and healthier outcomes for patients, health officials, labs and employers.
COVID-19 test results have been widely discussed as exceptionally emotional, as patients wait days if not weeks for results.
Delayed delivery of test results can impact a patient's ability to return to work or school or see loved ones who are sick or in nursing homes.
Meanwhile, every day test results are delayed, prospective carriers of COVID-19 may not be taking necessary precautions to prevent spread.
Healthvana enables labs and other providers to immediately contact patients via mobile and email as soon as the test results are available, dramatically reducing delivery delay from days to hours and eliminating thousands of hours in phone calls.
Healthvana's mission is to help eliminate COVID-19 using technology. Since 2015, the mobile-first patient portal has been enabling HIPAA-compliant test results to be easily and quickly distributed to patients.
Healthvana gives patients the ability to access their own health results anytime, while providing cities, labs, health systems, employers, skilled nursing facilities, homeless shelters and schools the ability to reduce costs, manage patient communication and inspire informed action for better outcomes.
Los Angeles-based Healthvana focuses solely on anxiety-provoking health information, and serves as the largest patient communication platform for COVID-19 and HIV in the US.
Bruker demonstrates advancements in 4D-Proteomics at US HUPO
Mitem Pharma acquires Flisint rights from Sanofi to address rare infectious disease
Audientes partners with Audivista to expand hearing solutions in Middle East and North Africa
Benuvia Operations signs licensing deal with Avernus Pharma
Benuvia Operations signs licensing and supply agreements with Medra Brasil Medicamentos
Castle Biosciences to present data on Melanoma tests at ASDP Annual Meeting
Alchemy partners with PatchRx to improve HIV medication adherence
Gilead expands global access to lenacapavir for HIV prevention